Allergic Rhinitis Treatment Market Size, Share and Global Trend By Application (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Treatment (Anti-histamines, Decongestants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Regional Forecast, 2024-2032

Allergic rhinitis, also known as hay fever is an allergic reaction towards allergens, causing inflammation of the nasal membrane. When a sensitive person inhales allergens such as pollens, grass, ragweed, cosmetics, cleaning agents or detergents, one may experience several symptoms characterized by sneezing, nasal itching, stuffy nose, nose blockages or congestions, puffy & swollen eyelids, and rhinorrhea.

Complications of allergic rhinitis may result in a decrease of focus & concentration, acute and chronic sinusitis, irritability, fatigue, sleep disturbance or apnea, and palatal abnormalities. Allergic rhinitis can be diagnosed with several allergic skin tests such as the intradermal test and prick/scratch test.

Other diagnostic test includes a blood test, RAST test, and others. According to the American Academy of Allergy, Asthma & Immunology (AAAAI), allergic rhinitis affects between 10% to 30% of the population worldwide every year contributing to the growth of global allergic rhinitis treatment market during the forecast period.

The factors boosting the allergic rhinitis treatment market are the prevalence of respiratory disorders due to high pollution levels and tobacco consumption. Also, other factors contributing to the growth of global allergic rhinitis treatment market are increased incidences of allergic rhinitis, rising pollution levels, rising funding for research & development, demand for early treatment due to efficiencies of diagnostic measures, and effectiveness of treatment associated with allergic rhinitis.

However, the factors limiting the growth of the global allergic rhinitis treatment market is increasing push for patients towards self-medication using over-the-counter medicines and also the side-effects associated with allergic rhinitis treatment.

Key Players Covered

Some of the major players in the global allergic rhinitis treatment market are GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ALK-Abelló A/S, Meda AB, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc. and others.

SEGMENTATION 

Among the segmentation, perennial allergic rhinitis in the application segment is anticipated to be the most lucrative owing to increasing alertness about perennial allergic rhinitis treatment among the patients.

Key Insights

• Prevalence of allergic rhinitis – Key countries,2018


• New Product Launch


• Pipeline Analysis


• Technological advancement in allergic rhinitis treatment


• Key mergers and acquisitions

Regional Analysis

Geographically, the global allergic rhinitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest share in the global market due to the prevalence of allergic rhinitis in the region, established healthcare system, high medical expenditure, access to advanced treatment solutions, demand for preventive care by diagnostic examinations, research funding for early treatment options, and higher awareness of allergic rhinitis. Asia Pacific is the fastest emerging market owing to increasing incidences of allergic rhinitis, large patient pool, rising demand for advanced treatment options, and rising healthcare expenditure due to greater disposable incomes. These factors are responsible for propelling the growth of the global allergic rhinitis treatment market during the forecast period.

Key Industry Developments

• In November 2018, Mylan N.V., announced the launch of DYMISTA a nasal spray for the treatment of allergic rhinitis patients in Malaysia.
• In February 2018, ALK announced the launch of sublingual allergy immunotherapy (SLIT) tablet ACARIZAX for patients suffering from house dust mite (HDM) allergic rhinitis and allergic asthma.
• In November 2017, Teikoku Seiyaku Co., Ltd. and Mitsubishi Tanabe Pharma Corporation launched RUPAFIN tablets for allergic rhinitis patients.